Effect of Treatment Delay on Survival in Patients With Cervical Cancer: A Historical Cohort Study

2014 ◽  
Vol 24 (7) ◽  
pp. 1326-1332 ◽  
Author(s):  
Tamar Perri ◽  
Gal Issakov ◽  
Gilad Ben-Baruch ◽  
Shira Felder ◽  
Mario E. Beiner ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cohort Study ◽  
Waiting Time ◽  
Treatment Initiation ◽  
Treatment Delay ◽  
Lymph Node Involvement ◽  
Continuous Variable ◽  
Node Involvement ◽  
Group 3 ◽  
Effect Of Treatment

ObjectiveThe objective of this study was to evaluate the effect of treatment delay on prognosis in patients with cervical cancer.MethodsThe study group of this historic cohort study comprised 321 patients newly diagnosed with cervical cancer between 1999 and 2010. Time from diagnosis to treatment was analyzed both as a continuous variable and as a categorical variable in 3 groups that differed in waiting time between diagnosis and treatment initiation: 30 days or less (group 1, n = 134), 30 to 45 days (group 2, n = 86), and more than 45 days (group 3, n = 101). Associations between waiting time group, patients’ characteristics, and disease outcome were investigated usingttests, analyses of variance and Cox regression analyses, Kaplan-Meier survival analysis, and log-rank (Mantel-Cox) tests.ResultsTime from diagnosis to treatment initiation, when analyzed as a continuous variable, was not a significant factor in survival. There were no between-group differences in age, smoking rate, marital status, gravidity, parity, tumor histology, or lymph node involvement. Early-stage disease and small tumor diameter were diagnosed most frequently in group 3. However, there was no significant between-group difference in 3-year survival rates (74.6%, 82.2%, and 80.8% in groups 1, 2, and 3, respectively;P= 0.38). On multivariate analysis, only stage, histology, and lymph node involvement were significant prognostic factors for survival. Before starting treatment, 28 patients underwent ovarian preservation procedures.ConclusionsLonger waiting time from diagnosis to treatment was not associated with worse survival. Our findings imply that if patients desire fertility or ovarian preservation procedures before starting treatment, it is acceptable to allow time for them.

scholarly journals Nm23 expression in endometrial and cervical cancer: inverse correlation with lymph node involvement and myometrial invasion

1996 ◽  
Vol 74 (7) ◽  
pp. 1063-1068 ◽  
Author(s):  
M Marone ◽  
G Scambia ◽  
G Ferrandina ◽  
C Giannitelli ◽  
P Benedetti-Panici ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Myometrial Invasion ◽  
Inverse Correlation ◽  
Lymph Node Involvement ◽  
Node Involvement

scholarly journals Does lymph node involvement affect the patterns of recurrence in stage IB cervical cancer?

2014 ◽  
Vol 44 ◽  
pp. 844-852 ◽  
Author(s):  
Işın ÜREYEN ◽  
Ülkü AKSOY ◽  
Betül DÜNDAR ◽  
Ömer Lütfi TAPISIZ ◽  
Mustafa Alper KARALÖK ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Lymph Node Involvement ◽  
Stage Ib ◽  
Node Involvement ◽  
Patterns Of Recurrence

Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment

Blood ◽  
2000 ◽  
Vol 95 (12) ◽  
pp. 3653-3661 ◽  
Author(s):  
Marcel W. Bekkenk ◽  
Françoise A. M. J. Geelen ◽  
Pieter C. van Voorst Vader ◽  
F. Heule ◽  
Marie-Louise Geerts ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Involvement ◽  
Lymphoproliferative Disorders ◽  
Group 4 ◽  
Long Term Follow Up ◽  
Node Involvement ◽  
Group 3 ◽  
Group 2 ◽  
Multiagent Chemotherapy ◽  
Group 1

Abstract To evaluate our diagnostic and therapeutic guidelines, clinical and long-term follow-up data of 219 patients with primary or secondary cutaneous CD30+ lymphoproliferative disorders were evaluated. The study group included 118 patients with lymphomatoid papulosis (LyP; group 1), 79 patients with primary cutaneous CD30+ large T-cell lymphoma (LTCL; group 2), 11 patients with CD30+ LTCL and skin and regional lymph node involvement (group 3), and 11 patients with secondary cutaneous CD30+ LTCL (group 4). Patients with LyP often did not receive any specific treatment, whereas most patients with primary cutaneous CD30+ LTCL were treated with radiotherapy or excision. All patients with skin-limited disease from groups 1 and 2 who were treated with multiagent chemotherapy had 1 or more skin relapses. The calculated risk for systemic disease within 10 years of diagnosis was 4% for group 1, 16% for group 2, and 20% for group 3 (after initial therapy). Disease-related 5-year-survival rates were 100% (group 1), 96% (group 2), 91% (group 3), and 24% (group 4), respectively. The results confirm the favorable prognoses of these primary cutaneous CD30+ lymphoproliferative disorders and underscore that LyP and primary cutaneous CD30+ lymphomas are closely related conditions. They also indicate that CD30+ LTCL on the skin and in 1 draining lymph node station has a good prognosis similar to that for primary cutaneous CD30+ LTCL without concurrent lymph node involvement. Multiagent chemotherapy is only indicated for patients with full-blown or developing extracutaneous disease; it is never or rarely indicated for patients with skin-limited CD30+ lymphomas.

Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment

Blood ◽  
2000 ◽  
Vol 95 (12) ◽  
pp. 3653-3661 ◽  
Author(s):  
Marcel W. Bekkenk ◽  
Françoise A. M. J. Geelen ◽  
Pieter C. van Voorst Vader ◽  
F. Heule ◽  
Marie-Louise Geerts ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Involvement ◽  
Lymphoproliferative Disorders ◽  
Group 4 ◽  
Long Term Follow Up ◽  
Node Involvement ◽  
Group 3 ◽  
Group 2 ◽  
Multiagent Chemotherapy ◽  
Group 1

To evaluate our diagnostic and therapeutic guidelines, clinical and long-term follow-up data of 219 patients with primary or secondary cutaneous CD30+ lymphoproliferative disorders were evaluated. The study group included 118 patients with lymphomatoid papulosis (LyP; group 1), 79 patients with primary cutaneous CD30+ large T-cell lymphoma (LTCL; group 2), 11 patients with CD30+ LTCL and skin and regional lymph node involvement (group 3), and 11 patients with secondary cutaneous CD30+ LTCL (group 4). Patients with LyP often did not receive any specific treatment, whereas most patients with primary cutaneous CD30+ LTCL were treated with radiotherapy or excision. All patients with skin-limited disease from groups 1 and 2 who were treated with multiagent chemotherapy had 1 or more skin relapses. The calculated risk for systemic disease within 10 years of diagnosis was 4% for group 1, 16% for group 2, and 20% for group 3 (after initial therapy). Disease-related 5-year-survival rates were 100% (group 1), 96% (group 2), 91% (group 3), and 24% (group 4), respectively. The results confirm the favorable prognoses of these primary cutaneous CD30+ lymphoproliferative disorders and underscore that LyP and primary cutaneous CD30+ lymphomas are closely related conditions. They also indicate that CD30+ LTCL on the skin and in 1 draining lymph node station has a good prognosis similar to that for primary cutaneous CD30+ LTCL without concurrent lymph node involvement. Multiagent chemotherapy is only indicated for patients with full-blown or developing extracutaneous disease; it is never or rarely indicated for patients with skin-limited CD30+ lymphomas.

A New MicroRNA Expression Signature for Cervical Cancer

2017 ◽  
Vol 27 (2) ◽  
pp. 339-343 ◽  
Author(s):  
Ping Sun ◽  
Yong Shen ◽  
Jiao-Mei Gong ◽  
Li-Li Zhou ◽  
Jia-He Sheng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Intraepithelial Neoplasia ◽  
Lymph Node Involvement ◽  
Healthy Controls ◽  
Aberrant Expression ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Node Involvement ◽  
Novel Biomarkers ◽  
Cancer Tissues

BackgroundCervical cancer is the second most common cancer among women worldwide. The potential of microRNAs as novel biomarkers in cervical cancer is growing.ObjectivesIn this study, we investigated the functions and targets of miR-466 in cervical cancer tissues.MethodsFresh cervical tissues were obtained from 157 patients with cervical cancer, cervical intraepithelial neoplasia (CIN), and healthy controls, and the tissues were immediately frozen in liquid nitrogen until use. The RNA was extracted and quantitative real-time polymerase chain reaction (PCR) was performed.ResultsA total of 157 participants were summarized, including 56 patients with cervical cancer, 60 patients with CIN, and 49 healthy controls. The expression levels of miR-466 in cervical cancers (0.68) were higher than that in healthy controls (0.082) (P < 0.01). The average fold changes of miR-466 in the patients with CIN group and people group were 0.28 and 0.082, respectively (P < 0.01). It was a statistically significant difference in patients with lymph node involvement (P = 0.022). However, the expression of miR-466 was not correlated with International Federation of Gynecology and Obstetrics stages, tumor size, or vascular invasion (P = 0.506, P = 0.667, and P = 0.108, respectively).ConclusionsOur results indicate that the aberrant expression of miR-466 is closely associated with the occurrence and development of cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document